News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec Canada Release: Health Canada Approves TECFIDERA™ as a First-Line Oral Treatment for Multiple Sclerosis



4/9/2013 10:36:41 AM

MISSISSAUGA, ON, April 9, 2013 /CNW/ - Today, Biogen Idec Canada announced the Health Canada approval of TECFIDERA™ (dimethyl fumarate) delayed-release capsules, formerly BG-12, as a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.1

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES